‘Unacceptable': Health insurer for 460K Mass. public workers goes broke without backup plan
But a Massachusetts group is calling it 'unacceptable' for the insurance agency to have a lack of backup options.
In January, The Group Insurance Commission (GIC) Executive Director Matthew Veno had flagged the agency's budget shortfalls as a concern.
'This is the largest variance that we've seen in at least a decade, and this is consistent across all of our plans, and is driven primarily by rising provider prices and a couple of other topics,' he said at the time. He added, 'We don't know where this is going to head. My concern is that it is a persistent and steady trend going forward.'
In April, Veno said rising provider prices and increased utilization of prescription benefits, including for GLP-1 weight loss drugs, had caused the commission to run an average $20 million monthly deficit this fiscal year.
With the fiscal year set to end June 30, the commission is counting on taxpayers to cover its deficit and has a $237 million appropriation request pending before the Legislature.
The appropriation was the largest single request in a $756 million spending bill Gov. Maura Healey filed in early April.
However, in an email sent to providers on Friday, the GIC warned that it 'does not know how soon the legislature will pass the bill and when the GIC will receive the requested funds.'
Instead, starting Monday, payment to providers for GIC member claims have been pending. They will remain pending until GIC receives the additional funds or until July 1.
The payment delay does not affect any other government programs, such as MassHealth or Medicare, according to the email.
The Massachusetts Health & Hospital Association (MHA) claims the disruption in payments 'will undoubtedly result in serious financial consequences.'
Other than the bill, the association points out the GIC did not have any other contingency plan to handle the problem despite saying the funding shortfall was a 'concern' since the beginning of the year.
Not looking at other options, MHA's Executive Vice President and General Counsel Mike Sroczynski said is 'unacceptable.'
'Massachusetts hospitals and health systems are not in a financial position to assume the budget shortfalls of the GIC program. While we appreciate the financial situation of the GIC, this directive is an unacceptable contingency plan to those challenges. We implore the GIC to seek an immediate, alternative resolution to its budget deficiency that will not further exacerbate the financial condition of healthcare providers,' Sroczynski wrote.
Veno said he isn't worried about 2026's budget.
In April, commission members asked about whether the GIC might need to adjust its fiscal 2026 budget request to reflect the higher fiscal 2025 costs. Veno said no adjustment is necessary.
'While we have been consistently running a deficiency, it's been pretty consistent. So we were able to build an FY '26 budget that reflects those trends,' he said.
State House News Service contributed to this reporting.
These surprising names topped the US fastest-growing baby names of 2024
Man dies in fire at his Marlborough home, no working smoke alarms found
Lowell man sentenced for trafficking over 11K fake Adderall pills containing meth
These are the most popular baby names of 2024: See the list
Waymo plans to map Boston area streets using its self-driving vehicles
Read the original article on MassLive.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business of Fashion
41 minutes ago
- Business of Fashion
Viking's GLP-1 Pill Results Mixed, Shares Slump
Viking Therapeutics said on Tuesday its experimental weight-loss pill helped people with obesity lose up to 12.2 percent of their body weight over 13 weeks in a keenly watched study. Yet, shares of the company slumped nearly 35 percent in premarket trading after data showed that more patients who received Viking's drug stopped taking the treatment, compared to those who received placebo in the mid-stage study. Oral drugs are expected to take a significant share of the projected $150 billion weight-loss market, driven by their ease of use compared with injections such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Viking's experimental oral pill is in a tight race with rival treatments being developed by the deeper-pocketed Novo and Lilly. Earlier this month, Eli Lilly said its experimental daily pill, orforglipron, showed a 12.4 percent weight loss in patients in a late-stage study over 72 weeks. In a separate trial, Novo's oral semaglutide has shown a weight loss of 15 percent over 68 weeks. Both the oral drugs are expected to be launched next year. Ahead of Viking's data, analysts expected weight loss in the range of 10 to 15 percent on average for the pill, known as VK2735. It had shown an 8.2 percent average weight-loss in a small early-stage trial. About 20 percent of those who received the drug discontinued due to an adverse effect, compared to 13 percent on placebo in the 280-patient study. The most common reasons for treatment discontinuation were gastrointestinal side effects, the company said. Like Lilly's Zepbound, Viking's drug also targets hormones known as GLP-1 and GIP that play a critical role in regulating the body's metabolism. Viking is testing both the oral and under-the-skin injection forms of the drug in overweight patients who have who at least one weight-related comorbidity. By Sriparna Roy and Siddhi Mahatole; Editors: Sriraj Kalluvila and Leroy Leo Learn more: GLP-1 Pills Will Be Priced Similarly to Injections, Wall Street Predicts US prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year will likely be on par with their weight-loss injections, analysts and investors say.
Fox News
2 hours ago
- Fox News
Cutting out alcohol and medicating sooner could prevent 'silent killer,' experts say
High blood pressure is a silent killer, experts warn, and nearly half of U.S. adults are at risk. Leading health groups say it's best to act sooner rather than later to prevent long-term damage — and they also recommend cutting out alcohol. The American Heart Association (AHA) and the American College of Cardiology (ACC) teamed up with 11 other organizations to release new guidelines, published Aug. 14 in the American Heart Association's peer-reviewed journals Circulation and Hypertension, as well as in JACC, the flagship journal of the American College of Cardiology. The new recommendations, which were refined through a rigorous peer-review process, represent the first major blood pressure update since 2017. The guidelines detail how doctors tackle high blood pressure and how people can take steps to manage their own, with a focus on prevention, early treatment and protection of both heart and brain health. "High blood pressure is the most prevalent and No. 1 modifiable risk factor for the development of cardiovascular diseases," Daniel W. Jones, M.D., chair of the guideline writing committee and professor emeritus of the University of Mississippi School of Medicine in Jackson, Mississippi, told Fox News Digital. "Members of the writing committee have been monitoring new evidence continually since the last guideline published in 2017," he added. Instead of using one-size-fits-all charts, the new approach focuses on the PREVENT (Preventing Risk of cardiovascular disease EVENTs) method, a tool that calculates a person's 10- and 30-year risk of heart attack or stroke. In addition to blood pressure, it also considers cholesterol, kidney health, metabolic issues and geographical location. The guidelines also urge doctors to act earlier. That could mean prescribing medication sooner or tapping into newer options like GLP-1 drugs for certain patients. Another new recommendation was to cut out alcohol — a change from the prior guidance for people to limit consumption. "We put forward the ideal as abstinence, and for those who choose to drink, less than one for women and less than two for men." "A lot of people enjoy drinking, but because the evidence is there, we want you to make an informed decision," Jones said. "There's a lot of individual variability with the relationship between alcohol and blood pressure, but we put forward the ideal as abstinence, and for those who choose to drink, less than one for women and less than two for men." Jones called the new alcohol guidance one of the two "most notable changes in the 2025 guidelines," along with reducing sodium intake from 2300 mg a day to 1500 mg a day. The experts also spotlighted the need to manage blood pressure during pregnancy to protect mothers and babies. Some of the prior standards still apply, like managing stress through exercise and maintaining a healthy weight, with a goal of at least a 5% reduction in body weight in adults who are overweight or obese. Nutrition remains a major factor, with recommendations to eat a healthy diet high in vegetables, fruits, whole grains, legumes, nuts and seeds, and low-fat or nonfat dairy, as well as lean meats and poultry, fish and non-tropical oils. For more Health articles, visit These habits, combined with earlier medical intervention when needed, could dramatically reduce long-term complications, experts say. The blood pressure criteria remain the same as the 2017 guidelines, as seen in the chart below. Research shows that controlling blood pressure earlier in life can also help prevent dementia and preserve brain health. "There is now more clear and robust evidence that intensive lowering of blood pressure reduces the risk of cognitive decline and dementia," Jones added.
CNBC
2 hours ago
- CNBC
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
Shares of Viking Therapeutics fell more than 30% in premarket trading Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors. The results could be a blow to Viking, which was once seen as a hot M&A target as pharmaceutical companies scramble to join the booming market for obesity and diabetes drugs. It could reinforce Eli Lilly and Novo Nordisk's dominance in the space, especially as they develop pills for weight loss that could enter the market years ahead of the tablet formulation of Viking's drug, VK2735. Jared Holz, Mizuho health care equity strategist, said in an email Tuesday that the data "probably shutters hope for [Viking] to be a bigtime player in the oral obesity market over the near to medium term." The race to develop a more convenient obesity pill has been fraught, as companies such as Pfizer have had to scrap previous contenders and bring forth new ones. Viking's once-daily pill helped patients lose up to 12.2% of their weight at around three months. The company also said that weight loss didn't plateau, which means patients could lose even more in a longer-term study. It's difficult to directly compare the pill's phase two trial data to the results of oral drugs further along in development, including treatments developed by Eli Lilly and Novo Nordisk. Holz added that the results on Viking's pill "look inferior" to those of Eli Lilly's oral drug "on almost all metrics." The highest dose of Eli Lilly's daily pill helped patients lose 12.4% of their body weight, or 11.2% regardless of discontinuations, at 72 weeks in a phase three trial. Holz pointed to the high rate of patients who discontinued Viking's drug for any reason over 13 weeks, which was around 28%. Meanwhile, around a quarter of people discontinued Eli Lilly's pill, orforglipron, for any reason over 72 weeks. That's "a much longer trial and therefore [Lilly] looks far better head-to-head," Holz said. Viking said the most common reasons for patients to discontinue treatment were gastrointestinal side effects, the majority of which were mild to moderate in severity and observed earlier in treatment. But around 58% of patients on the pill reported experiencing nausea and 26% experienced vomiting, compared to 48% and 10%, respectively, among those who took a placebo. Those side effect rates over a shorter trial period appear to be worse than those seen in trials on Eli Lilly's pill and the oral version of Novo Nordisk's weight loss drug Wegovy. Viking's treatment works by imitating two naturally produced gut hormones called GLP-1 and GIP. GLP-1 helps reduce food intake and appetite. GIP, which also suppresses appetite, may also improve how the body breaks down sugar and fat. Eli Lilly's pill and the oral version of Novo Nordisk's Wegovy both target GLP-1, but the latter has dietary restrictions.
